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1. INTRODUCTION 
 
Organophosphorus compounds have assumed considerable importance in most 
parts of the world. Though these compounds were discovered a century ago, even 
now they are the widely used insecticides all over the world. Poisoning with these 
substances is the commonest cause of inpatient mortality among all poisonings in 
developing countries like India. The toxicity of these compounds and paucity of 
appropriate medical facilities leads on to a high fatality rate. 
According to statistics, nearly 50% of the admissions with acute poisoning in 
emergency department are due to organophosphate compounds. Their easy 
accessibility along with socio-cultural factors play a considerable role in the 
selection of organophosphates as a main suicidal agent and is most often preferred 
by young economically productive age group with a case fatality ratio of around 20 
percent. 
WHO estimates about 3 million people are being exposed to pesticide poisoning 
every year with about 2,00,000 deaths per year in developing countries. India has 
the highest incidence of OP poisoning in the world. Nearly 90% of the poisoning 
are suicidal with a fatality rate of >10%; 8-10% accidental and <1% homicidal. 
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Occupational exposure accounts for 1/5
th
 of accidental poisoning with fatalities 
of<1%. 
               A history of exposure and signs of cholinergic overactivity helps in 
diagnosis of these poisonings.The treatment includes physiological antagonism 
with atropine or glycopyrrolate and oximes which help in reactivating the enzyme. 
Complications like respiratory failure , CNS depression and ventricular 
arrhythmias should be anticipated and treated. 
The organophosphate poisoning is associated with cardiac complications and most 
of them occur in the first few hours after exposure. Hypoxemia and electrolyte 
derangements are major predisposing factors for the development of these 
complications. 
Cardiac manifestations of these poisonings include hypotension ,hypertension, 
sinus bradycardia, sinus tachycardia and cardiac arrest due to arrythmias. 
Organophosphate compounds have been found to cause myocardial necrosis 
(myocardiotoxicity). Electrocardiographic changes in organophosphate compound 
poisoning have been reported along with the associated structural myocardial 
damage. If poisoning is recognized early and treated effectively, these 
complications can be prevented . 
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                Organophosphate compounds are not just cardiotoxic. They also 
influence neural dysfunction and brain damage by altering the normal internal 
milieu which leads to altered level of consciousness in such poisonings. Glasgow 
Coma Scale is widely used to assess the level of consciousness and to predict the 
prognosis in patients with cortical dysfunction.  
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2.AIMS AND OBJECTIVES 
 
 
 To assess  serum creatine phosphokinase (CPK) level in OP poisoning 
 
 
 To find out the correlation of serum creatine phosphokinase (CPK) level 
with the  severity of OP poisoning  
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3. REVIEW OF LITERATURE 
 
HISTORICAL REVIEW  
            During the past four decades, more than 35,000 different compounds have 
been introduced and are being used as pesticides. Of these, organophosphates are 
the most commonly used compounds globally. They have emerged as leading 
cause of ill health associated with pesticides all over the world.  
         Modern investigations of organophosphorus compound date from 1932 when 
LangeanKrugger recorded the synthesis of dimethyl and diethyl 
phosphofluoridates.They noted that these compounds caused a persistent choking 
sensation and blurring of vision. This observation led industries to develop 
organophosphorus compound,first as agricultural insecticides and later as potential 
chemical warfare agents. 
         Consequently, during World War II,several toxic compounds were developed 
and used as nitrogen gases in Germany. In 1991,these very compounds formed the 
cornerstone of Iraq‘s much dreaded chemical warfare arsenal during the Gulf war . 
Organophosphorus compound first came to India in 1951,to be used as insecticides 
and in 1962 first organophosphorus poisoning was reported in India. 
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CLASSIFICATION 
Holmstedt proposed a classification system for organophosphorus compounds that 
is of  pharmacological and toxicological interest. 
The compounds are divided into 5 groups with a few relevant examples. 
Group A: ( X: Halogen, Cyanide, and Thiocyanate ) 
      e.g.: Disopropylophosphatefluoridate( DFP) 
              Isopropyl methyl phosphofluoridate( SARIN) 
              Pinacolyl Methyl phosphofluoridate( SOMAN ) 
Group B: (X: Alkyl,alkoxy,aryloxy) 
      e.g.: Forstenon,DDVP,Pyrazoxon 
Group C: (X: Thiol or Thiophosphorus Compound) 
      e.g.: Parathion,Malathion, Azethion, Diazinon ,Systox and Demeton 
Group D: (Pyrophosphates and related compounds) 
    e.g.; TEPP,DPDA,OMPA 
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Group E: (Quaternary Ammonium Compound) 
   e.g.; Phospholin 
An older more commonly used classification divides these compounds into: 
1)Alkyl phosphates( e.g. TEPP,HETP,OMPA,Malathion,Systox,DFPetc., ) 
2) Aryl phosphates (e.g. Dimethoate,Parathion,EPN,Chlorothion,Diazinon,etc). 
These compounds are generally dispersed as aerosols / dusts ,consisting of 
organophosphorus compound adsorbed to an inert finely particulate material.  
Therefore practically all routes including gastrointestinal tract, respiratory tract and 
even intact skin on contact with the liquid form, rapidly and effectively absorb 
these compounds.The lungs also absorb them,after inhalation of the vapors or 
finely dispersed dusts/ aerosols. 
           Following absorption they quickly distribute to all tissues. In general, 
maximum concentration occurs in liver and kidneys. Lipophilic compounds may 
reach high concentration in neural and other lipid rich tissues. 
The route of administration and the type of compound determines the plasma half 
life of these substances and it varies widely from few minutes to few hours. 
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Metabolism occurs primarily by oxidation. Parathion is converted to biologically 
active compound – ―Paraxon‖ by microsomal activation in the liver. Malathion is 
less dangerous to man as they are metabolized rapidly to inactive compounds by 
the liver. 
         Highly lipid soluble agents such as Chlorfenthion may produce symptoms 
and signs of cholinergic over activity for an extended period of days to weeks, 
caused by subcutaneous lipid storage followed by subsequent chronic systemic 
release after redistribution. These compounds also cause repeated release after 
apparently successful management. 
             Detoxification of the organophosphorus insecticides occurs either by bio-
chemical modification of their structure or by linkage to the binding site without 
toxicological significance. 
Organophosphorus compounds and their metabolites are predominantly eliminated 
through urine and feces. These substances are usually eliminated as metabolites 
and nearly 90% of the substances are eliminated within 48 hours. Rarely few 
compounds are excreted unchanged in urine and feces while some of them may 
persist in the body for longer periods. The latter is the cause for delayed and 
prolonged complications of organophosphate compounds. 
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PHYSIOLOGY OF CHOLINERGIC TRANSMISSION 
                        Acetylcholine is the predominant neurotransmitter in all 
postganglionic autonomic fibers, postganglionic parasympathetic fibers, 
postganglionic sympathetic fibers, neuromuscular junction and some interneuron 
synapses in the CNS. 
 
 
 
 Acetyl choline is synthesized locally in the cholinergic nerve endings from 
choline, acetate , co-enzyme A and ATP. Most of the ACh is stored within small 
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vesicles in presynaptic membrane while some ACh is found free in the cytoplasm.  
Following stimulation of nerve endings, stored ACh is released into the synapse by 
exocytosis.    
                There are two classes of ACh receptors. 
1. Muscarinic and 
2. Nicotinic 
MUSCARINIC RECEPTORS: 
                 These are located primarily on autonomic effector cells in heart, blood 
vessels, eye, smooth muscles and glands of gastrointestinal, respiratory, urinary 
tracts and sweat glands. They are also seen in the CNS. There are 5 subtypes of 
muscarinic receptors. 
                 M1 - autonomic ganglia, gastric glands and CNS 
                 M2 – heart 
                 M3 – visceral smooth muscles, exocrine glands and vascular    
endothelium 
                 M4 – CNS 
                 M5 - CNS 
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NICOTINIC RECEPTORS: 
                   They are predominantly located in neuromuscular junction and 
autonomic ganglia. There are two types of these receptors. They are classified 
based on their location. 
N(m)  -  neuromuscular junction 
N(n)   -  autonomic ganglia and CNS 
                    The action of Acetyl choline in the body is terminated by its 
hydrolysis into acetate and choline. This is mediated by cholinesterases. There are 
two cholinesterases in the body namely acetyl cholinesterase (true cholinesterase) 
and butryl cholinesterase (pseudo cholinesterase).  
Acetyl cholinesterase hydrolyses acetyl choline very fast and is responsible for 
termination of ACh action within the body. It is seen at all cholinergic sites, RBC 
and gray matter. 
Butryl cholinesterase hydrolyses ACh slowly and is responsible for hydrolysis of 
ingested esters. This is seen in plasma, liver, intestine and white matter. These are 
more sensitive to inhibition by organophosphates and their levels fall drastically 
following inhibition with these compounds. 
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ANTICHOLINESTERASES : 
Anticholinesterases are agents which inhibit cholinesterase thereby protecting 
acetyl choline from hydrolysis. This results in potentiation of cholinergic effects in 
vivo. They can be classified into  
1. Reversible – physostigmine, neostigmine, pyridostigmine, edrophonium,  
rivastigmine, donepezil 
2. Irreversible – organophosphates and few carbamates. 
Anticholinesterases bind to and inhibit a number of enzymes,yet it is their action 
on the esterase which is of clinical importance. 
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a. Inhibition of Acetylcholinesterases (Ach E): 
. Acetylcholinesterases (AchE) are responsible for cleaving acetylcholine(Ach) to 
choline and acetic acid by hydrolysis . A potential reaction causes release of 
acetylcholine into synaptic cleft and Ach readily binds to the receptors in the 
postsynaptic membrane which leads to the generation of an excitatory postsynaptic 
potential and propagation of the impulse 
           Anti-acetylcholinesterase has two sites namely, anionic and esteric site. 
Acetylcholine binds to the anionic site on acetylcholinesterases and undergoes 
hydrolysis in a few seconds. Reversible anti- acetylcholinesterases combine with 
acetylcholinesterases at the anionic site and this blocks attachment of the substrate. 
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ORGANOPHOSPHATES: 
                     The organophosphorus compounds are the organic derivatives of 
phosphorus containing acids.The phosphonate, which are organic derivatives of 
phosphoric acid are not used as insecticides but are used as chemical warfare 
agents.These compounds are readily absorbed by inhalation, ingestion and through 
intact skin as they are lipid soluble. The chemical structure is 
 
Organophosphorus compounds combine with esteric sites of acetyl cholinesterase 
and phosphorylates it resulting in initial overstimulation followed by inhibition of 
synaptic conduction. 
                     Once phosphorylated, the enzyme will be inactive and cannot 
hydrolyze acetylcholine. This finally results in endogenous accumulation of 
acetylcholine at sites of cholinergic transmission and causes disruption of 
transmission of nerve impulses in both peripheral and central nervous system. 
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This binding is irreversible except with early pharmacological intervention.The 
rate of inactivation(phosphorylation) and reactivation (dephosphorylation) depends 
on many factors which lead to the differences in toxicity. Few of them are the 
chemical nature of the compound, metabolizing ability of the ingested species and 
the degree of tissue distribution. 
Reactivation of inactive cholinesterases occurs by two ways – by denovo synthesis 
of new enzyme which occurs very slowly at the rate of 1% per day and by 
spontaneous dephosphorylation. 
The phosphorylated enzyme is reacts very slowly or not at all with water. However 
if more reactive OH groups like oximes are used, reactivation occurs million times 
faster.  
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        Response to reactivating agents decline with time,a process referred to as 
‗aging‘ of the inhibited enzyme.It is a result of loss of an alkyl or alkoxyl group 
leaving a much more stable monoalkyl or monoalkoxylphosphoryl 
acetylcholinesterase. The aged phosphorylated enzyme cannot be reactivated by 
oximes.In chemical warfare agents like soman,aging occurs rapidly. 
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b. Inhibition of Neuropathy target esterase: 
Neuropathy target esterase(NTE) inhibition followed by its transformation to an 
aged form is responsible for the organophosphate-induced delayed 
neuropathy(OPIDN). 
PATHOPHYSIOLOGY 
The pathophysiological effects of organophosphates result from inhibition of 
cholinesterase (both RBC and pseudo cholinesterase).These are the markers of 
exposure,acute toxic effects and reflect actual activity at cholinergic nerve 
terminal. 
The serum cholinesterase levels are depressed within a short time in acute 
poisoning. A critical reduction of cholinesterase activity to less than 20% results in 
severe manifestations of cholinergic overactivity while signs begin to appear when 
their levels are depressed to 50%.  
There are many other causes of decreased cholinesterase levels. Severe 
malnutrition, liver disorders, pregnancy, both acute and chronic inflammatory 
states reduce the enzyme levels. Rarely the levels may be low due to genetic 
mutations. But the depression in cholinesterase levels is never severe enough to 
produce signs and symptoms. The enzyme levels slowly returns to normal when 
the primary disorder is treated.   
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OP pesticides inhibit acetylcholinesterase at muscarinic and nicotinic synapses by 
phosphorylation of the enzyme at its active site forming a temporary covalent bond 
which leads to increased availability of acetylcholine at the synaptic cleft and 
thereby resulting uncontrolled cholinergic over-activity. 
Over time, one of the two processes will occur. The covalent bond may 
spontaneously cleave leaving the enzyme functional again. This process may take 
upto1000 hours. Meanwhile the enzyme is prone to ―ageing‖ in its active site in 
which one of the ―R‖ group may cleave non-enzymatically, leaving behind a 
hydroxyl group. Once ‗aging‘ of the enzyme occurs, the inactivation cannot be 
reversed because the negatively charged phosphate group of the enzyme cannot be 
attacked by nucleophile like hydroxyl or oxime anymore. The enzyme is inhibited 
once for all. 
Recovery of a functional pathway must wait until new cholinesterase enzyme is 
produced,a process that may take weeks. The time it takes for ageing to occur 
varies according to the specific pesticide, but takes no longer than 48 hours. 
Clinically the toxic effects of OP agents may persist for more than a week. Oximes 
slows down ―ageing‖ of the phosphorylated cholinesterase and binds to the OP 
agent, making it non reactive. This results in cholinesterase regeneration and a rise 
in serum levels of cholinesterase. 
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CLINICAL FEATURES 
         The clinical manifestations of organophosphorus poisoning are a result of 
cholinergic over activity and can be divided into the effects of over stimulation of 
the muscarinic, nicotinic and CNS receptors. 
The type of agent, degree and route of exposure determines the time interval 
between exposure and clinical manifestations. The interval may be as less as 5 
minutes following massive ingestion and usually less than 12 hours .The severity 
of manifestation varies with the degree of poisoning. 
          In recent works, it has been reported that children, particularly less than nine 
years of age manifest ―nicotinic‖ signs rather than ―muscarinic‖ signs of poisoning. 
The most common features of paediatric poisoning are CNS depression and 
hypotonia. 
         The clinical diagnosis is based on: 
a. History of exposure 
b .The presence of several of the symptoms and signs such as garlic odour 
,secretions ,miosis , fasciculations,  respiratory failure etc as to be discussed below. 
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Muscarinic Receptors Nicotinic Receptors Central Receptors 
CVS Muscles  
Bradycardia Fasciculations Altered Consciousness 
Hypotension Weakness Respiratory Depression 
 Paralysis Cheyne-Stokes Respiration 
GIT Cramps Dysarthia 
Salivation CVS Tremors 
Nausea Tachycardia  
Vomiting Hypertension  
Abdominal Pain   
Diarrhea, urination   
Tenesmus   
Feacal Incontinence   
RS   
Bronchorrhea   
Wheezing   
Eye   
Miosis   
Lacrimation   
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Poisoning with organophosphorus compounds results in three clinical phases. 
1.Initial acute cholinergic crisis. 
2.The intermediate syndrome 
3.Delayed Polyneuropathy(OPIDN – Organophosphorus Induced Delayed 
Neuropathy) 
In addition chronic organophosphate induced neuropsychiatric disorder (COPIND) 
can occur. 
1. Acute cholinergic phase: 
       This is the initial phase of acute poisoning resulting in muscarinic and 
nicotinic effects. Cholinergic overactivity at muscarinic receptors results in 
excessive secretions in airways (bronchorrhea), oral cavity (salivation),sweat 
glands (sweating), gut (vomiting) and an increase in gastro-intestinal motility 
(abdominal tightness, cramps and diarrhoea). They also cause bradycardia and 
miosis(blurring of vision). 
        Excessive accumulation of acetylcholine at nicotinic sites like neuromuscular 
junction causes twitching of muscle (fasciculation). In the brain, acetyl-
cholinesterase inhibition causes headache  , insomnia ,giddiness ,confusion and 
drowsiness. Slurring of speech, respiratory depression, convulsions  and coma can 
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occur following severe poisoning. The mechanism of action for muscle paralysis is 
by depolarization blockade induced by acetylcholine at the neuromuscular 
junctions. 
                   Mortality in this initial phase of cholinergic over activity is due to 
either cardiac manifestations like bradycardia and arrhythmias or by respiratory 
failure and depression of vital centers in the brain. Cases with even vocal cord 
paralysis have been reported. Severe bradycardia may result in heart block. 
The cholinergic phase is a medical emergency and requires an early and intensive 
treatment to decrease the mortality rates.This phase usually lasts for 24 to 48 hours. 
2.Intermediate syndrome 
Senanayake and Karallieda first coined the term ―Intermediate syndrome‖ in 1987. 
Patients develop muscle weakness usually by 2- 5 daysafter recovering from the 
first phase. This weakness is different from the delayed polyneuropathy which 
usually occurs weeks after recovery from poisoning and is described as 
―Intermediate syndrome‖. 
development of IMS might be due to a conformational change in the acetylcholine 
receptor altering The depolarizing neuromuscular blockade to a   non-depolarizing 
blockade characterized by a fade on tetanic stimulation. 
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The classical feature of intermediate syndrome is proximal weakness of  limb 
muscles and neck flexors. Paralysis of motor cranial nerves (III to VII and X)can 
also occur. Respiratory muscle weakness leading to respiratory failure could lead 
to a fatal outcome. Deep tendon reflexes are usually depressed. 
               The intermediate syndrome occurs after recovery from the cholinergic 
crisis within 24 hours to 96 hours but before the expected onset of the delayed 
neuropathy, which occurs 2 to 3 weeks after the poisoning. Complete recovery 
requires adequate ventilator support and is usually needed for 4-18 days. The 
agents commonly responsible are fenthion , monocrotophos , dimethoate , diazinon 
and methyl parathion. 
3.Delayed Polyneuropathy 
                 The neuropathy develops following latent periods of two to four weeks 
after the initial cholinergic phase. Calf pain followed by predominant distal muscle 
weakness and accompanied by some form of paraesthesia involving the affected 
limbs are the cardinal features of this phase. Weakness initially appears in the calf 
muscles causing foot drop. This neuropathy may also involve small muscles of the 
hands and may extend proximally and even involve the muscles of trunk . Deep 
tendon jerks are absent. 
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The prognosis of patients is usually good in those with mild neuropathy but those 
with severe neuropathy are mostly left with persistent deficits like claw hand, foot 
drop, persistent atrophy and ataxias. Delayed polyneuropathy occurs following 
exposure to organophosphorus compounds with weak anti-cholinesesterase activity 
e.g. Triorthocresylphosphate. 
              The pathogenesis of delayed polyneuropathy is by phosphorylation and 
subsequent aging of an enzyme called neuropathy target esterase(NTE) which 
predominantly seen in axons. NTE is a membrane bound protein with high esterase 
catalytic activity. Apart from axons of the peripheral nervous system, it is also 
present in the brain and spinal cord .The exact function of this enzyme is not clear. 
But aging of the phosphorylated enzyme results in polyneuropathy. The agents 
commonly responsible are mepafox and chloropyrifos. 
Comparison between intermediate syndrome and delayed neuropathy 
 
 
 
Intermediate syndrome Delayed neuropathy 
Latent period 1-4 days 
2-3 weeks 
 
Site of weakness Proximal 
Distal 
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Chronic Organophosphate Induced Neuropsychiatric Disorder (COPIND) 
Behaviouraleffects have been documented following acute or chronic 
organophosphorus poisoning. These include 
a. Impairment of vigilance ,information processing, psychomotor speed and 
memory. 
b. Poor performance and perception of speech. 
c. Increased tendency to depression ,anxiety and irritability. 
c. A tendency to faster frequencies and higher voltages in EEG. 
Extrapyramidal manifestations (dystonia, rest tremors, cog wheel rigidity and 
chorea-athetosis) may occur four to forty days after organophosphoruspoisoning
 
.Recent studies suggest that Parkinsons disease is more common in patients who 
report to have had previous exposure to pesticides. 
EMG Tetanic fade 
Denervation 
 
Recovery 4 – 18 days 6 – 12 months 
OP agents commonly involved 
Fenthion, 
Dimethoate, 
Monocrotophos 
Methamidophos, 
Trichlorphos, 
Leptophos 
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GRADING OF SEVERITY IN OP POISONING 
Nambaet al have made a classification of organophosphorus poisoning insecticide 
which is modified from Grob et al and is as follows. 
Latent poisoning:- 
Clinically there are no manifestations of poisoning. The measurement of 
acetylcholinesterase levels in serum is used for diagnosis which is usually about 
50-80% of the normal. 
Mild poisoning:- 
Clinically  patient experience ‗SLUDGE‘ symptoms – excessive salivation, 
lacrimation , urination, sweating, diarrhea , gastrointestinal cramps and emesis. 
The levels of serum cholinesterase are reduced to 20-50% of normal values. 
Moderate poisoning:- 
 The manifestations are severe that the patient feels generalized weakness , miosis 
,muscular fasciculations and even difficulty to talk. Serum cholinesterase levels are 
10-20% of normal values. 
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Severe poisoning:- 
Patient is usually stuporous or unconscious with marked miosis and loss of 
pupillary light reflex. Secretions from the mouth and nose, bronchorrhea causing 
rales in the lungs , shallow respiration and cyanosis are frequently seen in patients 
with severe poisoning. Serum cholinesterase levels are lower than 10% of normal 
values. 
            However, this proposed grading has proved unworkable in clinical practice 
because of many varied clinical criteria in different grades, as well as the difficulty 
in remembering and applying then in acute clinical situation. 
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The second classification was proposed by Bardin et al and is as follows:- 
Grade 0 -Nil   :    Positive history 
                           No signs of organophosphorus poisoning. 
Grade 1-Mild  :   Mild secretions, few fasciculations, 
                           Normal level of sensorium. 
Grade 2-Moderate: Copius secretions, generalized fasciculations, 
                            rhonchi,crepitations, hypotension,  
                            disturbed level of consciousness. 
Grade 3- Severe:   Stupor, PaO2 < 50mmHg, Chest X ray  abnormal. 
                                      This study by Bardin et al showed that patients with grade 
3 manifestations on admission were associated with increased requirement for 
mechanical ventilation. The presence of other complications and increased days of 
ICU stay have been observed in the above patients. 
Grading of fasciculations 
                 Grading of fasciculation was done by giving score of 1 depending on the 
presence of fasciculations each to the anterior chest , posterior chest ,anterior 
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abdomen, posterior abdomen ,right thigh ,left thigh ,right leg ,left leg ,right arm 
and left arm. The total fasciculation score is thus estimated. 
Grading on the basis of cholinesterase values: 
Mild poisoning –serum cholinesterase levels decrease to 20 – 50%  
Moderate poisoning – serum enzyme levels decrease to 10 – 20%  
Severe poisoning – when enzyme levels fall less than 10% 
 
DIAGNOSIS 
Diagnosis depends on following factors:  
a. History or evidence of exposure to anticholinesterase agents. 
b. Signs and symptoms of poisoning. 
c. Improvement of these clinical features with atropine and PAM. 
d. Inhibition of cholinesterase activity. 
            The response to atropine therapy may also be useful aid to diagnosis, with 
patients who have organophosphorus  poisoning showing a tolerance to atropine. 
There is also failure to produce signs of atropinisation with 1 to 2mg of atropine 
administered intravenously. In most patients, a history of exposure to 
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organophosphorus insecticide can be obtained. A container is usually found. 
History may be denied in attempts of suicide or unavailable in patients who are 
found unconscious. Organophosphates impart a garlic like odour to the breath 
,vomitus or faeces .The signs of organo-phosphorus poisoning that are most helpful 
in diagnosis are miosis and muscle fasciculations. Others include excessive 
perspiration ,salivation,  lacrimation and bronchial secretion. 
          Inhibition of cholinesterase activity (50% reduction considered 
confirmatory) of the blood is also helpful. Estimation of erythrocyte cholinesterase 
(acetyl cholinesterase) is theoretically preferred as it reflects the degree of 
inhibition of synaptic cholinesterase. However, estimation of plasma 
cholinesterase(pseudo cholinesterase) can be done. 
           The various methods of estimating anti-cholinestersae activity are the 
electrometric method (widely used),the calorimetric method and a titrometric 
assay. 
           Estimation of blood sugar and urine acetone can help to rule out diabetic 
ketoacidosis since it is an important differential diagnosis of OP poisoning, yet OP 
consumption itself may cause hyperglycemia .Serum amylase level is said to rise 
and has prognostic significance. X ray chest can clearly show pulmonary 
congestion and edema indicating the severity of poisoning. 
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Differential diagnosis of organophosphate poisoning 
Acute poisoning 
Overdose – opiates, phenothiazine and nicotine 
Venomous arthropod bites – spider and scorpion 
Venomous snake bite 
Mushrooms containing muscarine 
Infective causes – pneumonia, sepsis, meningoencephalitis, botulism,  
Leptospirosis 
Neurologic causes – epilepsy, subarachnoid bleeding, subdural hematoma, pontine 
haemorrhage 
Metabolic causes – uraemia, hypoglycemia/hyperglycemia, myxedema coma, 
thyrotoxic crisis, Reye‘s syndrome     
Chronic poisoning  
Overdose – alcohol, opiates 
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Infective – gasteroenteritis, irritable bowel syndrome, bronchitis, asthma, chronic 
fatigue syndrome 
Neurological causes – Guillian Barre syndrome, motor neuron disease, depression, 
polyneuropathies 
Metabolic causes – chronic renal failure, thyrotoxicosis 
 
INVESTIGATION  
1. Arterial blood gas analysis. 
2. Estimation of serum and RBC cholinesterase. 
3. Blood sugar and serum electrolytes, amylase , lipase , creatinine . 
4. ECG 
5. Chest X-ray. 
6. Ultrasound scan of the abdomen (pancreatic status ). 
TREATMENT 
As like any poisoning, organophosphate poisoning is a medical emergency.  
A. Acute Cholinergic Crisis: 
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Management of the initial phase includes early implementation of the following 
principles.  
          a. Reducing further exposure and absorption of the pesticide. 
          b.Reversing the effects of the poison. 
          c.Maintaining vitals.  
           Regardless of nature of the compound, they are persistent on the body and 
clothing. They even penetrate the skin and clothing. Hence, immediate 
decontamination is mandatory. Clothing is discarded and the patient is mobilized 
away from the scene. Gentle washing of the body with soap water will help a lot. 
Do not wash eyes with any additional compounds other than normal saline, Ringer 
lactate or plain tap water.  Inhalational exposures are treated with removal of 
offending vapors and by administering oxygen. 
                                             Gastric decontamination is done by gastric lavage . It 
is ideally started within 30 minutes of exposure for effective decontamination but 
should never be delayed in those presenting late. If the patient is 
semiconscious/unconscious, Ryle‘s tube aspiration can be done. 
                                              Activated charcoal,1g/kg dose every 2-4 hours may be 
administered to reduce further absorption from the stomach except in cases of 
intestinal obstruction featured by absent bowel sounds and tense, rigid abdomen. 
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Respiratory failure is the usual cause of death in the acute phase; resuscitation and 
artificial respiration may be required immediately. Mouth-to-mouth respiration 
should not be attempted. Cardiac arrhythmias include various degrees of heart 
block and should be managed accordingly. 
  b. Reversing the effects of the poison by pharmacological antagonism: 
Atropine: 
    Treatment with anticholinergic medication is still the mainstay of treatment and 
should be started as soon as the airway has been secure. Full early atropinisation
 
 is 
an essential and simple part of an early management and a delay can result in death 
from central respiratory depression, bronchospasm , bronchorrhoea, severe 
bradycardia or hypotension. 
                  Atropine acts as a physiological antidote, effectively antagonizing the 
muscarinic receptor mediated action. It has virtually no effect against the 
peripheral neuromuscular dysfunction and subsequent paralysis induced by 
organophosphorus agent.   
                  The recommended dose is 2-4 mg intravenous, repeated at interval of 5-
10 minutes initially and continued until signs of atropinisation (dry axilla, clear 
lungs, no miosis, flushing of skin, systolic BP > 90 mm Hg and a heart rate of >80 
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beats/ minute) appear. Atropine therapy should be maintained until there is 
complete recovery. 
                The maintenance dose is said to be about 10% of the dose needed for 
atropinisation as continuous infusion and needs to be adjusted according to the 
toxic features on observation, as per recent API guidelines. 
                Infusion of atropine are used in some centers in dose of 0.02-0.08 
mg/kg/hr. Infusion of atropine has been postulated in greater decrease in mortality 
when compared with intermittent atropine administration. 
SOURCE RECOMMENDED 
REGIMEN FOR  
ATROPINISATION 
MARKERS OF 
ATROPINISATION 
CVS Muscles  
Harrison ‗s  
internal medicine 
19
th
 Edition,2016 
0.5mg repeated every 5-15 min Dry secretions 
Australian 
medicines hand 
book 14
th
 
Edition,2003 
2mg iv repeated until 
atropinisation is achieved then 
infusion titrated against clinical 
effects 
Abolish all secretions 
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British national 
formulatory 
Edition -46,2003 
2 mg repeated every 5-10 min. 
IM or IV according to severity 
Dry flushed skin,dilated 
pupils,tachycardia 
WHO model 
formulatory  
edition -1,2002 
2 mg repeated every 20-30 min  Flushed early skin and 
tachycardia 
 
PRECAUTIONS WITH ATROPINE THERAPY 
A heart rate exceeding 140beats/minute should be avoided. Atropine must be used 
carefully in patients with prior cardiac disorders. Large doses of atropine may 
cause ST changes in ECG. The cardiac adverse effects of atropine can be 
effectively countered by using propanolol. 
                                    Atropine crosses the blood brain barrier and may cause 
severe toxic effects such as convulsions , psychosis and coma , which if necessary 
should be corrected with physostigmine . 
LIMITATIONS OF ATROPINE 
1. Has no nicotinic action 
2. Has no effect on respiratory centre in presence of severe asphyxia 
3. No effect once hypotension develops 
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4. In the presence of cyanosis, it may precipitate ventricular fibrillation. 
Glycopyrrolate: 
This is a quaternary ammonium compound that can be used as an alternative to 
atropine. 
The advantages of glycopyrrolate over atropine are  
a. Better control of secretions. 
b. Less tachycardia 
c. Fewer CNS side effects 
 
Oximes: 
Oximes regenerates the inhibited acetylcholinesterase rapidly at muscarinic, 
nicotinic and CNS sites. The widely available oximes are Pralidoxime (Pyridine-2-
aldoxime methyl chloride, PAM) and Obidoxime. The other available oximes are 
Trimedoxime,Asoxime,HI6,HI07 etc. 
                 The reactivating action of pralidoxime is most marked at the skeletal 
neuromuscular junction. It acts by reactivation of the inhibited phosphoryrlated 
enzyme to free the active form. Its dose is 500 mg/hour for severe poisoning and  
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1gm 8-12  hourly for mild moderate poisoning in adults and 25-50 mg/kg in 
children , given intravenous in 250ml normal saline over 30 minutes. 
                         The WHO recommended pralidoxime regimen is 30 mg/kg bolus 
followed by 8 mg/kg infusion. It has no muscarinic effect . It has short half-life of 
1.2 hours when given intravenous and does not cross the blood brain barrier.PAM 
should be administered as early as possible, at least within 4-36 hours of poisoning 
for regeneration of anticholinesterase. It is dependent primarily on the life span of 
the erythrocytes when aging of the enzyme has occurred. 
                        PAM is available as chloride, iodide, meslyate and methyl sulphate 
salts .The chloride salt is more stable than iodide in dry state and is preferred for 
intramuscular use. 
                         The major pharmacological action of oximes is to reactivate 
anticholinesterase by removal of phosphate group bound to the esteric site .This 
action occurs shortly after poisoning and inhibition of the enzymes, after which the 
enzyme ages and becomes more firmly bound to esteric site. Oximes should be 
given as soon as possible before aging takes place. They are most effective if given 
within 6 hours of poisoning, but beneficial response is seen upto 24 hours of 
poisoning. 
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                           The therapeutic effects of oximes seemed to depend on the plasma 
concentrations of the organophosphorous agent with the benefit being, minimal at 
high concentrations of organophosphorous in the blood.Pralidoxime does not cross 
the blood-brain barrier whereas obidoxime does. 
                            Adverse effects of therapeutic doses of PAM in humans have 
been absent or minimal and may not be evident unless plasma levels are greater 
than 400 mg/ml. Transient dizziness, blurred vision and elevation in diastolic blood 
pressure may be related to the rate of administration. Rapid i.v. administration has 
produced sudden cardiac and respiratory arrest.  Paradoxically high doses of 
pralidoxime may cause neuromuscular block and other effects including inhibition 
of anticholinesterase. High frequencies of cardiac arrhythmias were observed in 
patients who received high cumulative doses of atropine and obidoxime. 
SUPPORTIVE THERAPY 
Diazepam: 
Diazepam is used to treat convulsions after organophosphorus poisoning and in the 
support of ventilator care. Few reports suggest that diazepam can act 
synergistically to oximes and atropine. They act by counteracting the CNS effects 
of organophosphates by unknown mechanisms. 
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Diazepam 5-10 mg iv is given slowly over 2-3 minutes. Repeat after 10-15 
minutes. Monitor blood pressure and respiration.    
Phenytoin: 
Phenytoin is also used to treat seizures associated with organophosphate poisoning. 
The usual dose is 10-20 mg/kg.It is given at the rate of 50 mg/min through 
intravenous route. Patient must be monitored for cardiotoxicity.  
Fluoride: 
           Fluoride and atropine combination has a greater antagonistic effect than 
atropine monotherapy. The use of fluoride was tried following observations from 
workers of factories dealing with fluoride compounds. They were found to have 
higher levels of cholinesterase level in blood. 
Magnesium: 
           Kiss and Fazekas reported that intravenous magnesium sulfate can be used 
successfully to treat ventricular arrhythmias
 
. Magnesium primarily antagonizes the 
inhibition of sodium-potassium ATPase by organophosphates. 
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Respiratory stimulants: 
           Respiratory stimulants are contraindicated in the management of 
organophosphorus poisoning especially when the patient has features of 
neuromuscular weakness, bronchospasm and convulsions . 
Other measures: 
Dialysis of blood against activated charcoal (hemoperfusion) is effective in 
demeton-S-methyl sulphoxide, dimethoate and parathion poisoning. Prompt 
improvements have been reported following repeated injections of purified 
lyophilized human cholinesterase.  
                              Resealed cells containing a recombinant phosphodiesterase 
provided protection against the lethal effect of paraoxon. Phosphodiesterase 
hydrolyses paraoxon to the less toxic 4-nitrophenol and diethylphosphate. This 
enzyme was encapsulated into carrier erythrocytes by hypotonic dialysis with 
subsequent resealing and annealing. The encapsulated enzyme was found to persist 
longer and possess much greater efficacy. When these cells were administered in 
combination with pralidoxime chloride and atropine ,a marked synergism was 
observed .The use of fresh plasma and exchange transfusions are of little value. 
Corticosteroids, camphor, potassium chloride , clonidine  and vitamin C have been 
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used with varying degree of success . However all these regimens need further 
evaluation. 
Intermediate Syndrome - Management: 
                                      Respiratory failure is the cause of death in patients with 
intermediate syndrome. Early identification and effective management of 
respiratory failure is the cornerstone in the treatment of IMS. 
                                     Patients are observed for signs of respiratory failure and 
facilities for ventilatory care are made available. Arterial blood gas analysis is 
helpful in monitoring and weaning the patients from ventilator support. Diazepam 
10 mg intravenous doses may be useful in anxious or restless patients on ventilator. 
Management of Delayed Neuropathy: 
      No specific treatment has been fruitful. Physiotherapy and exercises are tried 
with variable success. 
COMPLICATIONS OF OP POISONING: 
        Complications resulting from organophosphorus poisoning occur in about 
43% of cases with acute intoxication.Death can often occur early(within 24hours) 
in untreated cases and upto 10 days in hospital with optimal management. 
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                           Early deaths are due to CNS depression, seizures, and ventricular 
arrhythmias (e.g.,Torsades de pointes) or respiratory failure due to excessive 
bronchial secretions , pulmonary edema , aspiration pneumonia , respiratory 
muscle paralysis or respiratory centre depression. 
                         Late mortality is caused by respiratory failure associated with 
infection (pneumonia, septicemia) or ventilator related complications.There are 
various studies in which respiratory failure was the commonest complication 
encountered following acute organophosphorus poisoning.  
                       The pathogenesis is multifactorial and related to aspiration of gastric 
contents, excessive secretions in the airways, pulmonary infections, pneumonia , 
septicemia and development of ARDS. Respiratory consequences of muscarinic 
overstimulation including rhinorrhoea, bronchorrhea, broncho-constriction and 
laryngeal spasm contribute to respiratory failure. These are often combined with 
nicotinic effects such as respiratory muscle weakness and paralysis (including 
paralysis of tongue and nasopharynx). 
                        Central depression of respiratory centre occurs following 
cholinergic overstimulation of synapses in the brain stem and is a prominent cause 
of hypoxia, respiratory failure and death in the early period of acute 
organophosphorus poisoning. 
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                           Peripheral neuromuscular block producing respiratory muscle 
weakness and paralysis as well as the recently described intermediate neuropathy 
contributes to the development of respiratory insufficiency at a later stage. 
                            Sudden cardiovascular collapse is often the first indication of 
unsuspected or incipient respiratory failure , a presentation that is associated with a 
high mortality. 
                            The development of pneumonia is the most important cause of 
delayed respiratory failure after organophosphorus poisoning and this occurs in 
upto 43% of the patients  . Upto 80% of patients with pneumonia had respiratory 
failure ,majority of these could be diagnosed within 96 hours of poisoning. 
TREATMENT OF RESPIRATORY FAILURE 
Clinical factors influencing the decision to initiate mechanical ventilation in acute 
respiratory failure are 
 Evidence of fatigue of respiratory muscles (e.g., weak and ineffective 
respiratory effort, paradoxical abdominal movement) 
 Altered consciousness 
 Circulatory collapse – fall in blood pressure and urine output 
 Inability to expectorate secretions 
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                                     Failure of oxygenation is primarily treated with 
supplemental oxygen to raise the inspired oxygen concentration (FiO2). Low flow 
oxygen delivery systems (Nasal prongs, venture face- masks) do not attempt to 
satisfy inspiratory flow requirements completely; room air is entrained diluting the 
effective FiO2.  
                                   Delivery systems with reservoirs (moustache, pendant and 
non-breather mask) increase effective FiO2 by satisfying a greater proportion of 
the inspiratory flow requirement. High flow systems also attempt to do this by 
limiting the extent of room air entrainment. Realistically, however, it is unlikely 
that FiO2 of more than 80% can be advised with any of these systems. Continuous 
positive airway pressure can be added via a tight fitting face mask to recruit 
collapsed alveoli and improve gas exchange. 
                                       When low flow or non invasive supplemental oxygen 
systems fail to sustain adequate PaO2, further intervention (intubation, mechanical 
ventilation) is needed. Intubation allows addition of positive end expiratory 
pressure (PEEP) to recruit collapsed alveoli, increase functional residual capacity 
and improve gas exchange. 
                                     PEEP is typically 5-15 cm of water but depending on 
clinical circumstances, it must be titrated carefully to avoid decrease in venous 
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return and cardiac output or c pulmonary barotraumas that could result in 
pneumothorax. Addition of PEEP can avoid prolonged use of higher FiO2. Severe 
chronic hypoxaemia requires long term supplemental oxygen therapy(LTOT); 
provision of portable oxygen systems is important. 
                                           Failure of ventilation is primarily treated by mechanical 
ventilation. Acute failure of ventilation can be treated non-invasively, provided 
respiratory acidosis is not life threatening. The usual approach is non-invasive 
positive pressure ventilation via a tight fitting facemask. 
                                              Severe uncompensated hypoxemia despite non 
invasive treatment requires endotracheal intubation and conventional positive 
pressure ventilation. During intermittent positive pressure ventilation (IPPV) the 
work of breathing is taken over as augmented by mechanical ventilator. All 
ventilators deliver a predetermined volume or pressure but there are many 
variations and refinements. 
                                             Volume preset ventilators deliver a constant flow of 
gas and the pressure generated by the machine is that required to achieve a 
predetermined tidal volume. Pressure preset ventilators deliver a constant pressure 
and the resulting tidal volume depends on lung and chest wall mechanics. 
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                                 The timing of the inspiratory and expiratory phase can be 
adjusted and positive pressure can be administered during expiration (PEEP). 
Ventilation may be provided totally by the machine or the patient can inhale some 
or all breaths. This facilitates transition from fully supported ventilation to 
spontaneous breathing. Ventilation can be delivered invasively or non invasively. 
                                 Intubated,  paralysed  patients are totally dependent on the 
ventilator and close nursing supervision and correctly set alarms to warn about life 
threatening conditions are necessary. All ICU ventilators continuously monitor 
inspired oxygen fraction (FiO2, airway pressure and tidal, inspired and expired 
minute volume), monitoring of physiological variables also facilitates choice of 
ventilation mode, optimization of settings and maximization of cardiovascular 
function to optimize blood gas tensions and oxygen delivery. 
                                         PEEP may be useful in patients with reduced lung 
compliance (stiff lungs) because it improves gas exchange and reduces the work of 
breathing. In patients with stiff lungs, addition of PEEP allows a reduction of FiO2 
thereby reducing risk of oxygen toxicity. It also has a beneficial effect on the lung 
mechanics because it shifts tidal breathing on to a more compliant part of the 
pressure-volume curve. 
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                                          In patients with incomplete alveolar emptying during 
expiration, the pressure in the alveoli at end expiration remains positive during 
spontaneous breathing; this is termed ‗intrinsic PEEP‘. This positive pressure must 
be overcome before inspiratory flow can occur and respiratory work is wasted 
decompressing gas; this is so called ‗Inspiratory threshold load‘ can be 
counterbalanced by the addition of extrinsic PEEP during ventilation. 
                                       Tracheostomy can be inserted percutaneously in an ICU. It 
reduces the need for sedation, promotes laryngeal competence and may be helpful 
in weaning by reducing the wasted ventilation of the anatomic dead space. 
                                    Weaning of the patients from assisted to spontaneous 
ventilation is achieved by synchronized intermittent mechanical ventilation or by 
pressure support ventilation or spontaneous breathing on a T piece. 
Prevention: 
        Preventive measures should be considered at all the levels of the chain of 
insecticide movement through the environment-formulation, manufacture, mixing 
application and disposal. 
       Psychiatric counseling for prevention of second episode should always be 
given. General counseling and drug therapy for depression should be added. Strict 
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guidelines should be adopted during transport and storage to prevent contamination 
of food, clothing, drugs,  toys, cosmetic and furnishing. 
TREATMENT OF ORGANOPHOSPHORUS POISONING 
Severity Treatment 
Latent Unnecessary, but observe for atleast 6 hours 
Mild Pralidoxime 1g iv and atropine sulphate 1 mg s.c. 
Moderate Pralidoxime 1 g iv q4-6 hr for minimum of 24-48 hrs; 
atropine sulphate 1-2 mg iv every 20-30 min until 
bronchial secretions, sweating and salivation 
disappear and there is slight mydriasis 
Severe Pralidoxime 2 gm iv followed iv infusion of PAM @ 
o.5g/hr for minimum 24 – 48 hrs; Longer therapy for 
fat soluble agents (IMS).  Atropine sulphate 5mg 
every 20-30 min until bronchial secretions, sweating 
and salivation disappear and there is slight mydriasis; 
diazepam for seizures.  
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This treatment is in addition to normal decontamination procedures and basic 
management.  
 
OTHER EFFECTS OF ORGANOPHOSPHORUS INTOXICATION: 
Altered immunity to infection: 
In 1974,Bellin and Chow suggested that organophosphorus agents might have an 
effect on the human immune system.  Casali et al demonstrated that parathion 
suppressed both the primary IgM and IgG response to sheep erythrocytes in mice. 
Newcombe showed an increased incidence of lympho-proliferative disorders 
associated with impaired natural killer cell and cytotoxic T-cell function. 
Murray et al reported influenza like symptoms in 23 patients after occupational 
exposure to organophosphorus compounds. 
Changes in metabolism and endocrine activity: 
In animal experiments , changes in the diurnal pattern of plasma ACTH have been 
reported following organophosphorus poisoning. Nicotinic receptors also function 
in brain pathway that increases the release of several pituitary hormones including 
vasopressors, ACTH and prolactin. In man, nonketotic hyperglycemia may occur. 
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Effects on Reproduction: 
 There is a report of termination of pregnancy following organophosphorus 
poisoning during the first trimester. In experimental animals , organophosphorus 
poisoning during pregnancy cause pre- and postnatal death and congenital 
abnormalities such as vertebral deformities ,limb defects , polydactyly and cleft 
palate. 
Gastro Intestinal effects: 
Profuse diarrhea for 2 to 5 days after ingestion of organophosphorous insecticides 
has been reported. 
Renal effects: 
Immune complex neuropathy with renal dysfunction and massive proteinuria can 
occur several weeks after malathion exposure. C3 levels marginally decrease and 
renal dysfunction resolves spontaneously after 1 month. 
Temperature Regulation: 
After exposure to most organophosphorus compounds , a marked hypothermia 
response lasting up to 24 hours has been demonstrated. 
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SERUM CHOLINESTERASE AND SEVERITY OF OP POISONING: 
An old school of thought is that the definitive laboratory diagnosis of 
organophosphorus compound poisoning is the measurement of enzyme activity. 
Many methods are available to determine the levels of acetylcholinesterase and 
butrylcholinesterase. The commonly used one is the measurement of catalytic 
activity. 
 Plasma butrylcholinesterase activity correlates poorly with acetylcholinesterase 
activity in the brain and is no longer considered to be a marker of severity of 
poisoning and prognosis. The reasons are 
 Butrylcholinesterase is synthesized in liver. The activity of the enzyme 
levels alter in liver disorders. 
 Inherited variants with altered enzymatic activity are common. 
  Most of all, these enzymes are different from acetyl-cholinesterase in many 
aspects – substrate affinity, inhibition, reactivation and ageing. 
 The enzyme levels are falsely low in conditions like pregnancy, infection 
neoplasia and medical illness. 
Plasma cholinesterase levels can be easily assayed and hence they are widely 
used. Though unreliable in predicting severity, they can be used as a marker for 
diagnosis. 
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              Serum cholinesterase levels do not correlate with the severity always. 
The baseline serum enzyme level varies widely between individuals. Hence a 
single value cannot assess the severity but a fall in levels on serial follow up 
will help in determining the prognosis.                     
On the other hand, RBC cholinesterase activity is a better predictor of severity 
because 
 The neuronal acetyl-cholinesterase and RBC cholinesterase are products of 
same gene. 
 The half life for recovery of the enzyme is same as that of RBC as it cannot be 
re-synthesized in the red blood cell. 
 Both the plasma and RBC cholinesterase are easily inhibited by the agents 
when compared to complex location of neuronal counterparts. 
 
But the erythrocyte cholinesterase can be falsely low in hemolytic anaemias, 
hemoglobinopathies and pernicious anemias. 
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Creatine phosphokinase 
 
Creatine phosphokinase catalyses the reversible phosphorylation of  
creatine by  ATP. Creatine kinase activity is high in striated muscle and heart.  
Brain , GIT and  urinary bladder contain less activity of CPK.  Liver and RBCs are  
devoid of activity. 
 
         CPK contains two subunits , each with molecular weight of 40,000 Da .  
These are products of two different loci on Chromosome 14 and 19. 
 
 There are three different forms 
 CPK 1 – BB 
 CPK 2 – MB 
 CPK 3 – MM  
All the three are associated with myofibrillar structures and found in the cytosol of   
the cell. There is a fourth form that differs from others immunologically by  
electrophoretic  mobility. It is present in between the inner and outer mitochondrial  
membrane. They are  called CPK- Mt .  In the heart it constitutes 15% of the CPK  
activity CPK activity is found in macro molecular form hence called  macro CPK . 
It  is  found  transiently in upto 6% of hospitalized patients . 
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 It exists in 2 forms . 
Type 1/  CPK –BB with an immunoglobulin complex form – no  
specific role. 
Type 2 / CPK—Mt oligomeric form .This is present in adult patients  
who are severely ill with malignancy or  
liver disease and in children who have notable  
tissue distress. 
 
Appearance of this   iso-enzyme is associated with poor prognosis. Macro  
CK Assay can interfere with the assay of CK-MB. 
 Causes of elevation of CK  
Injury  
Inflammation 
Necrosis of skeletal/heart muscle 
Drug intake – Statin , fibrates ,  ART, ARBs 
Poisoning and snake bite. 
 
 
Creatine kinase is elevated in all types of muscular dystrophy. In progressive  
muscular dystrophy enzyme activity in serum is initially high at the time of infancy  
and childhood , characteristically fall when functioning muscle mass is reduced. 
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NEED FOR SCORING SYSTEMS 
 
There is a greater need for understanding the clinical characteristics of OP and 
carbamate  poisoning, since in majority of the situations, the exact causative agents 
remain unknown and there is lack of analytical assistance in most of the primary 
health care systems. Majority of the physicians depend purely on clinical signs and 
symptoms as a guide for diagnosis. 
 However, the onset of symptoms may take some time to develop in poisoning with 
some agents, by then the toxicity might become irreversible or even fatal. 
Intentional OP poisoning is a medical emergency which requires prompt treatment. 
OP poisoning has high inpatient mortality and many patients have cardio-
respiratory arrests after admission (38% of cases need intubation in one study). A 
substantial number of deaths can be prevented with proper management of 
repiratory failure. 
 Hence, it is important to identify the factors which help in prediction of respiratory 
failure in an early stage which will help in early institution of ventillatory support. 
This will facilitate the selection of patients needing intensive management. 
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A number of scoring systems have been proposed for predicting outcome in OP 
poisoning. Many are reliant on laboratory tests and are therefore, less useful in 
resource poor locations.  
Studies are necessary as to whether it was possible to predict inpatient mortality in 
OP poisoning using a scoring system based on simple clinical parameters recorded 
solely at admission. This might enable clinicians to identify patients at high risk of 
dying soon after presentation, allowing more intensive monitoring and treatment. 
But those studies that use clinical parameters have been validated using small 
number of patients. 
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5. MATERIALS AND METHODS: 
 
STUDY POPULATION:  
                    This study was conducted among 100 patients who are admitted in 
Govt. Rajaji hospital, Madurai with history and features of organophosphate 
poisoning. 
 
INCLUSION CRITERIA: 
 Patients > 18 years 
 Patients with history of exposure to OP poisoning within 6  hours 
 
EXCLUSION CRITERIA: 
 Patients with indication of exposure to an entirely different poison 
other than OPC Poison. 
 Patients with OP poisoning and mixed with any other  poison 
 Patients who have consumed poison along with alcohol 
 Patients who are chronic alcoholics 
 Patients with history suggestive of chronic liver disease 
 History suggestive of myopathy 
 Patients with history of malignancy and autoimmune diseases 
 Patients with history of renal  disease 
 History of intake of drugs like,– 
Eg:     Statins, Fibrates, Dexamethasone 
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ANTICIPATED OUTCOME: 
              Patients with initial  high CPK values and those who have a non declining 
trend  are associated with increased morbidity and mortality and thereby require 
intensive care monitoring. It might be helpful in predicting and assessing the 
prognosis of patients of OP poisoning . 
 
DATA COLLECTION : 
            A previously designed profoma will be used to collect the demographic and 
clinical details of the patients. An intial CPK value will be determined and follow 
up values will be taken on days 1,4 and 7.   
 
STUDY PROTOCOL: 
Initial CPK values and further follow up values will be determined and they will be 
compared with the severity of poisoning as suggested by dosage of atropine and 
pralidoxime used, development of complications like respiratory failure and 
outcome. The outcome would be classified into survival with or without ventilator 
assistance and death. 
LABORATARY INVESTIGATIONS: 
1) Blood :HB ,TC ,DC ,ESR 
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2) ECG 
3) Random blood sugar   
4) Blood Urea 
5) Serum creatinine 
6) Serum creatine kinase 
7) LFT:    
    a.SGPT  
    b.SGOT 
8)  Any other  relevant  investigations  if  indicated  
 
SPECIMEN COLLECTION: 
Use un-hemolysed serum or plasma ( EDTA / Heparin) 
It is recommended to follow NCCLS procedures  
 
CREATINE  PHOSPHOKINASE  ESTIMATION: 
Diagnostic reagent for quantitative in-vitro determination of  
creatine phosphokinase in human serum and plasma . 
 
REAGENTS COMPOSITION : 
Reagent 1 – CPK Nac reagent  
Imidazole buffer pH 6.1          
Glucose 
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Magnesium acetate 
EDTA 
Nacetyl cysteine 
NADP 
Hexokinase  
 
REAGENT 2 / CPK Nac REAGENT  
ADP 
D-glucoso 6 phosphate dehydrogenase Creatine phosphate 
AMP 
Diadenosine penta phosphate 
METHODOLOGY: 
                    International federation of clinical chemistry. 
 
PRINCIPLE: 
Creatine phosphate + ADP   ------------  Creatine + ATP 
D glucose + ATP ------------------------- ADP + Glucose 6 phosphate 
Glucose 6 phosphate + NADP 
+ 
---------6 phosphogluconate + NADPH
+  
H
+ 
 
STABILITY:  
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1 week at 2-8
o
C 
1 day at 15-25
o
C 
4weeks at -20 
o 
C 
Discard contaminated specimen . 
 
Expected values at 37
o
C  : 
Males – 46-172 U / L  
Female—24- 145 U/L 
 
DESIGN OF STUDY: Hospital based prospective observational study. 
 
PERIOD OF STUDY: March 2016 to August 2016(6 months) 
 
COLLABORATING DEPARTMENTS: Department of Biochemistry 
ETHICAL CLEARANCE: obtained 
CONSENT: Individual written and informed consent. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  NIL 
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PARTICIPANTS: 
             Patients of age >18yrs, admitted as in-patients at Govt. Rajaji hospital, 
Madurai with features of organophosphate  poisoning 
 
STATISTICAL ANALYSIS 
 
The data collected in the study was formulated into a master chart in Microsoft 
Office excel and statistical analysis was done with help of computer using 
statistical software package SPSS V.17 for Windows.  
                   Using this software, frequencies, range, mean, standard deviation and 
percentages were calculated.  
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OBSERVATIONS  AND RESULTS 
 
1. Age distribution: 
 
Table 1 : Age distribution among OP poisoned cases 
AGE No. of Cases % 
19—30 37 37.00 
31—40 21 21.00 
41—50 23 23.00 
51—60 16 16.00 
>60 3 3.00 
Total 100   
 
Fig 1: Bar diagram depicting the age distribution among OP poisoned cases. 
 
2. Gender distribution: 
 
37 
21 23 
16 
3 
0
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30
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19--30 31--40 41--50 51--60 >60
No. of Cases
66 
 
   Table 2 : Gender distribution among OP poisoning patients. 
 
 
 
 
 
 
Fig 2 : Pie chart showing the gender distribution of OP poisoning cases.  
            Out of 100 patients  67 were males and 33 females . 
 
 
 
 
 
63% 
37% 
Male
Female
Sex 
No. of 
Cases 
% 
Male 63 63.00 
Female 37 37.00 
Total 100 100.00 
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3. Exposure 
 
Table 3:  Type of exposure: 
Type of 
Exposure 
No. of 
Cases 
% 
ACCIDENTAL 6 6.00 
INTENTIONAL 94 94.00 
Total 100 100.00 
 
 
Fig3 :  Pie chart depicting the type of exposure to OPC poisoning.  
           Of the 100 cases the most common type of exposure was suicidal. 
 
 
 
 
6% 
94% 
ACCIDENTAL
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4. Reason  for OPC poisoning 
 
Table 4 :  Depicting the Reasons for consumption 
Reason No. of Cases % 
Familial 66 66.00 
Financial 15 15.00 
ill Health 7 7.00 
Job stress 6 6.00 
Others 6 6.00 
Total 100 100.00 
 
 
Fig 4 : Bar diagram depicting the common reasons for OPC consumption. 
Familial  problems were 66 % and was identified as the most common cause of OP  
poisoning. 
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5. Agents responsible for OPC poisoning : 
 
Table 5: Agents responsible for  OP poisoning  
Agents 
No. of 
Cases 
% 
Bug killer 
liquid 13 
13.00 
Chlorpyrifos 9 9.00 
Dichlorofos 4 4.00 
Fenthion 7 7.00 
Monocrotophos 8 8.00 
Methyl 
parathion 52 
52.00 
Quinolphos 7 7.00 
Total 100 100.00 
 
Fig 5: Pie chart shows distribution of type of OP consumed  
Methyl parathion was found to be the most common compound 
 
13% 9% 
4% 
7% 
8% 
52% 
7% 
AGENTS  
Bug killer liquid Chlorpyrifos Dichlorofos Fenthion
Monocrotophos Methyl parathion Quinolphos
70 
 
 
6. Mode of consumption: 
 
Table 6 : Mode of consumption  
Mode of 
Consumption of 
poison 
No. of 
Cases 
% 
With Milk 34 34.00 
Others 18 18.00 
With Water 48 48.00 
Total 100 100.00 
 
 
 
 
 
Fig 6 : Pie diagram depicting the mode of comsumption of poisoning. 
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7. Clinical features : 
 
 
 
Fig : 7 This bar diagram shows the distribution of studied patients according 
to the characteristic symptoms and cholinergic toxidrome . 
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Fig 8 : Scatter diagram depicting the correlation between CPK levels and 
requirement of atropine. 
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Fig 9 : Scatter diagram depicting the correlation between the initial CPK level 
and Pralidoxime dosage 
 
 
      
Total % CPK vs Out 
Come 
survival Death 
<390 78 0 78 78.00 
391--600 1 5 6 6.00 
>600 0 16 16 16.00 
Total 79 21 100 100.00 
P'Value 0.012       
 
Table 7 : Shows correlation between  Creatine Phosphokinase and out come of 
the patient. 
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Figure 10 : Bar diagram showing the correlation between the creatine 
phosphokinase and severity of the poisoning . 
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Fig 11 : This Bar diagram depicts the duration of ventilatory support required 
for the Organophosphorus  poisoning  patient. (+) represents the requirement 
of ventilatory support.  
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Fig 14: This line diagram shows the relationship between the initial CPK     
levels and Mortality of the patient. 
If initial CPK level is high ( > 600 ) in Organophosphorus poisoning , patients 
mortality is high.  
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Table 8 : Comparison of the initial and final serum creatine phosphokinase 
levels of studied patients  
This study was done to asses if the initial serum CPK level can be used as a  
biomarker of severity of OPC poisoning . The present study found that the initial  
serum CPK level is elevated in  acute OPC poisoning provided that exclusion of  
any other disease or conditions that may cause rise in CPK levels. This study was  
found to be statistically significant and the p value was < 0.05. 
 
 
 
 
 
 
  Mild  (<390) 
Moderate (390 - 
600) Severe  (> 600) 
CPK LEVEL  (IU/L) Mean SD Mean SD Mean SD 
Initial CPK 225.59 56.301 492.667 70.955 751.188 91.327 
Final CPK 121.013 27.613 1076.333 554.485 1138.188 248.646 
    < 0.001  Significant  0.028  Significant 
  < 0.001  
Significant 
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6. DISCUSSION 
 
 Organophosphorus (OP) compounds are among the most commonly used  
 
pesticides in agriculture. Because of their wide use and easy accessibility, OP  
 
toxicity is important global health problem especially in many developing  
 
countries [21, 22]. Every year, hundreds of thousands of deaths occur worldwide  
 
due to poisoning with OP compounds [23].  
 
 
Inhibition of acetylcholinesterase is regarded as the major toxic mechanism of OP,  
of  cholinesterase inhibition [24]. Despite the benefits of acetylcholinesterase 
which leads to excess stimulation of muscarinic and nicotinic receptors. The 
typical clinical picture of cholinergic crisis develops fast, being the basis for 
clinical diagnosis, which is confirmed by the history and demonstration 
monitoring, this test is not available in most parts of the developing world in which  
there is a high caseload of OP poisoning [25].  
Weissmann-Brenner et al [26] Reported  that 66% of patients with OP poisonings  
were males and 34% were females, 39% were less than 10 years old, 64% of 
exposure was accidental, 36% was suicidal and  the most common route of  
intoxication was oral (67%).   
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In our study illustrated that most of patients manifested with vomiting and 
abdominal pain  (100%), followed by depressed mental status (25%), pinpoint 
pupil (24%) fasciculation (21%), respiratory failure (21%) and convulsions (10%)  
Researchers [27] in their study on OP intoxicated patients  reported that the most 
frequent clinical signs were bronchial hypersecretion (52%),  tachycardia (47%), 
meiosis (45%), salivation (41%), and bradycardia (31%).  Because an increase of 
serum CPK concentration always reflects injury to a tissue  of high CPK activity, 
CPK measurements are particularly useful in the diagnosis of  many medical 
conditions like acute myocardial and acute skeletal muscle injuries . [28]. 
Traditional theories relate this CPKemia to agitation, hyperactivity and drugs (i.e. 
rhabdomyolysis and muscle necrosis) [29]. The present study showed that there 
was a high degree of correlation between the initial serum CPK levels and the 
severity of acute OP poisoning; as illustrated by the positive correlation of initial  
serum CPK level with (total dose of atropine in "mg" and pralidoxime in "g"). 
These correlations were found to be statistically highly significant (P < 0.001).  
These results are in agreement with Bhattacharyya et al [14] who confirmed the 
presence of a high degree of correlation between initial CPK value and POP scale,  
serum AChE levels, arterial pH values and total dose of atropine in acute OP  
poisoning. 
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Muscle fiber necrosis and consequently raised CPK levels occur in severely acute   
OP poisoned cases [30, 31]. So, cheaper, easily quantifiable and more available  
biochemical markers in relation to OP poisoning like serum CPK can be used in 
predicting as well as assessing the prognosis of patients with OP poisoning [14].  
The severity of OP poisoning in this study ranged from mild, moderate and severe;  
most of cases were presented with mild OP toxicity. Authors [16] Illustrated that 
the POP scale can efficiently predict the severity of OP poisoned patients.  
Meanwhile, authors [32] stated that POP scale uses high respiratory rate and 
cyanosis, and this approach is likely to be misleading in severe OP poisoning as 
patients may have either a reduced respiratory rate or tachypnea.  
                                          Geller et al [33] highlighted that the total amount of 
atropine is correlated with severity of OP poisoning, as severely poisoned patients 
require very large doses (up to 100 mg over a few hours) of atropine determined by 
chemical titration and control of muscarinic symptoms. Researchers [27, 34] 
reported that there was a significant  negative linear correlation between the GCS 
scores and severity of OP intoxication.  
                                                Aygun et al [35] illustrated that physicians usually 
request the BChE activity level to confirm the diagnosis of symptomatic patients 
with OP poisoning, to classify the severity, and to aid management follow up [36, 
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37] highlighted the benefits of measuring the BChE activity levels in predicting 
successful weaning of patient from mechanical ventilation in severe OP poisoning 
as well as in improving the outcome. On the other hand, authors [38] stated that 
BChE measurement on admission has been used to stratify OP poisoning severity. 
However, it may not be helpful since different OP compounds inhibit BChE to 
differing degrees compared to their inhibition of the clinically important AChE. 
BChE activity therefore does not always reflect severity and it must be interpreted 
carefully. In the present work, the elevated serum CPK levels were confirmed 
during the  acute stage of toxicity i.e. all cases presented within 6 hours of 
exposure to OP  compounds and before the development of the intermediate 
syndrome. This was in agreement with authors [14] who confirmed in their study 
on OP intoxicated patients that serum CPK level is elevated even in the absence of 
intermediate syndrome presumably due to muscle fiber necrosis.  
                                              Intermediate syndrome occurs in between the periods 
of acute and delayed OP toxicity. The majority of reported cases of intermediate 
syndrome occur in patients 24–96 hours after acute OP  poisoning [7, 45]. 
Meanwhile authors [46] had linked the raised CPK levels to the  rhabdomyolysis in 
―intermediate syndrome‖. But authors [47] highlighted that  muscle injury begins 
during the cholinergic crises and the severity of muscle injury  is correlated to the 
severity of the cholinergic crises. The excess acetylcholine seen  in OP poisoning 
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leads to reversible myocyte injury and rise of different muscle  enzymes, including 
CPK. The present work highlighted the importance of serial  measurement of 
serum CPK levels, as it might be helpful in predicting as well as assessing the 
prognosis of patients with acute OP poisoning. As follow-up serum CPK levels 
measured in recovering patients without any complications during the therapy 
course showed a tendency to decrease. This was in agreement with Sahjian and 
Frakes [48] who stated that if there is ongoing injury to the muscle due to 
development of complications, the CPK level continues to be elevated, since half-
life of CPK is about 1.5 days; it normalizes within 5–6 days of a single insult  to 
the muscle.  
                                           Counselman et al [49] stated that CPK levels peak 
within 24 to 48 hours of the onset of muscle injury or rhabdomyolysis and then 
decline at the relatively constant rate of 39% of the previous day's value. The 
present study found that the initial serum CPK level is comparable for BChE level 
and can be used as an alternative biomarker in diagnosis of acute OP poisoning, 
provided that exclusion of any other diseases or conditions that may cause rise in 
CPK levels, these results were statistically significant (p < 0.05). This was in 
agreement with Perreault et al [50] who confirmed that when a skeletal muscle is 
injured, CPK leaks into the blood and urine.  
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                                             Serum CPK level remains the best biomarker for 
detecting and monitoring skeletal muscle damage and diseases. Also authors [14] 
confirmed the elevation of serum CPK levels in acute OP poisoning, especially if 
the patient is severely poisoned, presumably due to muscle fiber necrosis. 
However, the main disadvantage of serum CPK as a biomarker for acute OP 
poisoning, its non-specificity. So, exclusion of other conditions and diseases that 
may cause its elevation in patients with acute OP poisoning is mandatory.   
 
                  We evaluated 100 patients admitted following consumption of  
organophosphorus compounds in Government Rajaji Hospital, Madurai.                    
Respiratory failure occurs in two forms, early and delayed. Early respiratory failure 
occurs soon after admission while the delayed form occurs several hours to 5 days 
after admission. The mechanism of respiratory failure is likely to involve three 
components, including depression of central respiratory drive from respiratory 
centre, respiratory muscle weakness and direct pulmonary effects such as 
bronchorrhea and bronchospasm.  
                                                     In our study there is a direct correlation between 
the initial CPK levels and severity of poisoning. Hence the patients prognosis is 
bad when the initial CPK levels are high. 
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LIMITATION OF THE STUDY 
 
Since the study was based on assessing the parameters at admission, none of those 
who developed intermediate syndrome were predicted of developing respiratory 
failure. 
This study Has its own limitation .the number of patients in this study is small . 
hence generalization of results of the study have to be made with caution. 
The study population involved patients seeking medical care in our hospital which 
is a tertiary care centre and hence they may not represent the general population. 
This study is an observational study longitudinal study with serial measurement of 
variables would be more informative .So , longitudinal studies with large study 
population based studies are needed to circumvent this limitation. 
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CONCLUSION 
 
Organophosphorus compounds are commonly used agents for suicidal purpose 
because of their easy availability. The main determining factors for mortality are 
the type of poisonous agent used, the severity of the poisoning, the stage at which 
treatment is started and the presence or absence of intensive care facilities.  
                 The organophosphate poisoning is associated with cardiac complications 
and most of them occur during the first few hours of poisoning. Hence early and 
adequate atropinisation will reduce the mortality to a great extent. 
Respiratory failure is the commonest cause of death in OP poisoning. Though 
ventilators are boon to patients with respiratory failure, early identification and 
intensive management are vital in reducing the mortality.  
              Our study shows that respiratory failure in patients with OP compound 
poisoning can be predicted at admission by simple parameters like 
CreatinePhosphokinase(CPK). This prognostic parameter can help doctors at 
peripheral health centres in successfully predicting outcomes and thereby high risk 
cases are referred to higher centres without any delay. In this way, the incidence of 
complications and mortality in OP poisoning can be reduced. 
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In the study  a progressive increase in Creatine Phosphokinase levels CPK with 
increasing severity of poisoning was observed , reflecting the possible correlation 
of OPC poisoning and Creatine Phosphokinase levels . CPK levels . 
                                     CreatinPhosphokinase levels may be considered as a 
prognostic marker of OPC intoxication since it enables the early recognition of 
severity and also helps to identify those at risk of developing the delayed 
complications of OPC poisoning .It was observed that hypersecretion depressed 
mental state ,miosis , fasciculation were greater in those with high CPK levels . It 
was found that incidence of respiratory depression and intermediate syndrome was 
high in those with marked increase in those with creatine phosphokinase levels. It 
was also found that mean days of mechanical ventilation , intensive care stay and 
in hospital stay correlated with severity of poisoning , those with high levels of 
Creatine Phosphokinase levels . 
It was noted that upon treatment ,levels of creatine phosphokinase revert to normal 
followed  by an improvement in the clinical condition of the patient .In the mean 
dose and duration of Atropine and pralidoxime treatment can be optimized , since a 
need for higher doses in severe cases has been evident . 
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PROFORMA 
 
A STUDY OF CREATINE PHOSPHOKINASE IN PREDICTING 
PROGNOSIS AND OUTCOME OF ORGANOPHOSPHATE POISONING 
 
PARTICULARS OF THE PATIENT : 
Name :                                                                                                           Case no : 
Age/ Sex : 
I.P. no : 
Address : 
Date of admission : 
Date of discharge : 
Accidental or suicidal : 
Final diagnosis : 
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COMPLAINTS WITH DURATION : 
Time and date of consumption of the poison : 
Time between poisoning and admission : 
Quantity consumed : 
Mode of conception : 
Features of poisoning : 
                        Vomiting/diarrhoea 
                        Frothing from mouth or nose 
                        Sweating 
                        Altered sensorium 
                        Altered breathing 
                        Convulsions 
                        Other complaints  
Past history : 
Personal history : 
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Family history : 
On Examination,  
Vital signs              Pulse :                              B.P. :                                     R.R. : 
SpO2 :                              Temperature : 
Breath smell : 
Cyanosis : 
Diaphoresis : 
Frothing from nose or mouth : 
Respiratory pattern : 
C.N.S. : 
             Sensorium – normal / restlessness / drowsiness / stuporous / comatose 
Pupils : 
Fasciculations : 
Weakness :    nil / proximal muscle / neck muscle / respiratory muscle  
             If respiratory muscle weakness is present,  
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a. Single breath count : 
b. Accessory muscle : 
ABDOMEN : 
CVS : 
RS :clear / secretions 
 
DIAGNOSIS : Organophosphate or Organocarbamate poisoning 
Mild  /  Moderate /  Severe   Poisoning 
 
MANAGEMENT : 
                                     Dose within first 48 hours                  Dose after 48 hours of 
Admission 
Atropine : 
P2AM : 
Need for mechanical ventilation : 
Time duration between consumption and starting mechanical ventilation ( hrs):           
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Intermediate syndrome : 
Any other complications : 
Recovered without  mechanical ventilation 
               Recovered with mechanical ventilation 
               Expired inspite of mechanical ventilation  
Duration of  
ICU Stay ( hrs )         : 
Hospital Stay ( hrs )  :                   
OUTCOME : 
 
LABORATORY INVESTIGATIONS : 
              S. Electrolytes :            Na -               K -                 Ca -                 Mg -  
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ABBREVIATIONS: 
OPC – organophosphorus compounds 
GCS – Glasgow Coma Scale 
ACh- acetyl choline 
AChE – acetyl cholinesterase 
NTE – neuropathy target esterase 
CPK – Creatine phosphokinase  
IMS – intermediate syndrome 
OPIDN – organophosphate induced delayed neuropathy 
PAM – pralidoxime 
TdP – torsades de pointes 
EAD – early after repoarisation 
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KEY TO MASTER CHART : 
 
 TYPE OF EXPOSURES  
                 I     -    INTENTIONAL 
                A     -    ACCIDENTAL 
REASON FOR CONSUMPTION 
               Fa   -   Familial 
               Fi   -   Financial 
               J     -    Job stress 
               I     -    Ill  health  
               O   -    Others 
MODE OF CONSUMPTION 
              W   -   Water 
              M   -   Milk 
              A    -   Alone 
              O    -   Others 
AGENTS 
             Mp   -   Methyl parathion 
             B      -   Bug killer liquid 
             F      -   Fenthion  
             Q     -   Quinolphos 
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             Mo  -   Monocrotophos 
           C      -   Chlorpyrifos 
           D     -    Dichlorofos 
CLINICAL FEATURES 
           P     -    Pinpoint pupil 
          M    -    Depressed Mental status 
          S     -    Secretions    +      Mild 
                                         ++   Moderate 
                                         +++ Severe 
         F      -    Fasciculation 
         H     -    Heart rate     -   B   -  Bradycardia 
                                           -    T   -  Tachycardia 
                                           -    N  -  Normal 
         C     -    Convulsions 
        RF     -    Respiratory  failure 
        IMS    -   Intermediate  syndrome 
         CPK – Creatine phosphokinase  
 
  
       TREATMENT 
       A      -     Mean Dose of Atropine  mg/day 
       P      -     Mean Dose of Pralidoxime   g/day  
104 
 
       V      -     No. of days in ventilation  
       ICU  -     No. of days in ICU 
       HS   -     Hospital  Stay  
       O     -     Outcome       -    S   -  Survival     D – Death 
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MASTER CHART 
S.No Age Sex EX RE Agents MODE Clinical Features CPK Levels on day Treatment 
P M S F H C RF IMS 1 2 3 4 7 A P V ICU HS O 
1 32 M I Fa MP W - - ++ - N - - - 234 247 171 122 87 20 4 0 0 4 S 
2 31 M I Fa F W - - ++ - N - - - 184 172 112 94 54 20 3.5 0 0 4 S 
3 22 F I Fa B M - - ++ - N - - - 92 84 77 76 62 10 3.5 0 0 4 S 
4 41 F I Fa MP M + + +++ + B + + - 442 562 602 728 892 110 5.5 5 7 10 D 
5 19 F I Fa MP O - - ++ - N - - - 154 132 112 94 87 20 4 0 0 4 S 
6 44 M I J D W + + ++ + T - - - 169 182 161 135 98 25 3.5 0 0 5 S 
7 28 M I Fa B W - - ++ - N - - - 98 84 112 103 67 20 4 0 0 4 S 
8 52 M a Fi MO M + + +++ + B - + - 875 987 1023 2215 0 135 5.5 4 4 4 D 
9 24 M I Fa MP W - - ++ - N - - - 321 211 198 161 98 55 5.5 0 0 5 S 
10 38 F I Fa Q O - - ++ - N - - - 184 171 152 113 87 20 3.5 0 0 4 S 
11 45 F I Fi MO W + + +++ + B + + - 872 954 1032 1872 0 135 5.5 4 4 4 D 
12 43 M I J MP M - - ++ - N - - - 272 302 212 174 113 40 4 0 0 5 S 
13 24 M I Fa Q W - - ++ - N - - - 164 191 154 103 87 25 3.5 0 0 4 S 
14 32 F I Fa MP O - - ++ - N - - - 294 278 212 162 131 40 4.5 0 0 6 S 
15 27 F I Fa B W - - ++ - N - - - 194 174 152 113 93 20 3.5 0 0 5 S 
16 59 M I I MP M - - ++ - N - - - 432 534 332 273 152 80 5.5 0 0 8 S 
17 42 M I Fa MP W - - ++ - N - - - 172 161 143 114 87 25 3.5 0 0 6 S 
18 20 M I Fa MP W - - ++ - N - - - 231 194 176 143 109 25 3.5 0 0 6 S 
19 36 M I Fa B W - - ++ - N - - - 154 139 117 98 83 25 3.5 0 0 4 S 
20 44 F I O MP M - - ++ - N - - - 212 178 154 123 103 25 4 0 0 5 S 
21 43 M I Fa C W + + ++ - B + + + 564 823 948 1027 2064 135 5.5 5 5 7 D 
22 25 F I Fa MP W - - ++ - N - - - 172 143 113 98 87 20 2.5 0 0 6 S 
23 61 F I I F M + + +++ + B + + - 678 874 978 1047 1088 110 5 7 7 10 D 
24 38 M I Fa MP M - - ++ - N - - - 223 312 242 154 142 35 4 0 0 6 S 
25 43 M I O MP O - - ++ - N - - - 247 184 157 142 131 40 4 0 0 7 S 
26 19 M I Fa Q W - - ++ - N - - - 194 172 167 132 142 30 3.5 0 0 4 S 
27 41 M I J B W - - ++ - N - - - 232 198 181 147 138 30 4 0 0 6 S 
28 25 F I Fa MP M - - ++ - N - - - 143 157 124 138 141 35 3.5 0 0 5 S 
29 28 F A Fa C M - - +++ - N - - - 328 297 249 187 152 40 4.5 0 0 6 S 
30 53 F I Fi MP O - - ++ - N - - - 221 183 162 148 137 35 4 0 0 7 S 
31 24 M I Fa MO O + + +++ + B + + + 847 997 1028 1084 2041 130 5 5 6 10 D 
32 21 M I Fa MP W - - ++ - N - - - 184 172 167 141 112 25 3.5 0 0 5 S 
33 47 M I Fa B W - - ++ - N - - - 172 181 154 137 123 20 3.5 0 0 5 S 
34 22 M I Fa MP W - - ++ - N - - - 243 189 162 153 131 30 4 0 0 4 S 
35 36 M I Fa F M + + +++ + B + + - 558 747 894 947 1068 110 5 5 7 9 D 
36 60 F I I MP M - - ++ - N - - - 197 183 154 161 123 20 3.5 0 0 4 S 
37 29 F I Fa MP W - - ++ - N - - - 312 248 187 173 151 35 4 0 0 6 S 
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38 53 M I Fi D M + + ++ + T - - - 223 201 162 151 112 25 3.5 0 0 5 S 
39 34 M A Fa MP W - - ++ - N - - - 181 162 171 123 141 25 4 0 0 5 S 
40 19 F I Fa C M - - ++ - N - - - 322 287 224 197 167 35 4 0 0 6 S 
41 33 F I Fa MP M - - ++ - N - - - 213 183 164 131 114 30 3.5 0 0 4 S 
42 27 M I Fa Q M - - ++ - N - - - 358 298 256 218 198 50 4.5 0 4 8 S 
43 54 M A Fi MP W - - ++ - N - - - 221 197 181 149 118 20 3.5 0 0 5 S 
44 56 F I I MP W - - ++ - N - - - 198 164 139 121 143 25 3.5 0 0 5 S 
45 47 M I Fi C O + + +++ + B - + - 647 728 894 927 1084 110 5 6 8 10 D 
46 28 M I Fa MP M - - ++ - N - - - 204 187 164 171 151 20 4 0 0 5 S 
47 61 M I Fi MP M - - ++ - N - - - 312 298 252 162 113 30 4 0 0 6 S 
48 37 F I Fa F O - - ++ - N - - - 348 297 262 213 192 50 4 0 0 6 S 
49 45 F I Fa C W + + +++ + T - + - 827 944 1028 1162 - 130 5.5 4 4 4 D 
50 32 M I O MP W - - ++ - N - - - 221 184 172 154 121 30 3.5 0 0 5 S 
51 25 M I Fa MO W + + +++ + B + + - 684 729 857 978 1024 120 5 6 9 11 D 
52 52 F I Fi MP M - - ++ - N - - - 197 181 153 131 98 35 3.5 0 0 4 S 
53 49 M I J B M - - ++ - N - - - 213 207 182 167 144 30 3.5 0 0 5 S 
54 28 F I Fa MP O - - ++ - N - - - 201 183 172 162 139 25 3.5 0 0 5 S 
55 37 F I Fa MP M - - ++ - N - - - 249 258 211 154 113 30 4 0 0 6 S 
56 41 F I J MP M - - ++ - N - - - 187 173 142 138 97 20 3.5 0 0 5 S 
57 29 M I Fa MO W + + +++ + B - + - 744 892 927 998 1059 110 5 7 9 11 D 
58 52 M I Fi MP W - - ++ - N - - - 167 149 132 121 112 20 3.5 0 0 4 S 
59 59 M I I Q M - - ++ - N - - - 258 211 194 187 122 40 4 0 0 7 S 
60 23 M I Fa MP M - - ++ - N - - - 176 152 141 119 97 25 3.5 0 0 4 S 
61 44 M I Fa F O + + +++ + B - + - 778 847 984 1078 1144 120 5 6 7 10 D 
62 28 F I Fa MP W - + ++ - N - - - 198 183 164 149 118 30 4 0 0 5 S 
63 61 F I Fi MP M - - ++ - N - - - 203 179 132 117 87 25 3.5 0 0 4 S 
64 47 F I J D W + + ++ - T - - - 243 219 193 164 142 30 4 0 0 6 S 
65 51 M I Fi MP O - - ++ - N - - - 187 172 153 121 117 20 3.5 0 0 4 S 
66 33 F I Fa MP M - - ++ - N - - - 223 198 187 154 128 25 4 0 0 5 S 
67 24 M I Fa C W + + +++ + B - + - 548 647 842 997 1058 110 5 5 7 10 D 
68 19 F I Fa MP W - - ++ - N - - - 312 298 257 168 152 30 4 0 0 6 S 
69 36 M I O B W - - ++ - N - - - 226 211 184 162 147 25 3.5 0 0 5 S 
70 43 M A Fa MP W - - ++ - N - - - 298 252 213 149 121 30 4 0 0 5 S 
71 26 M I Fa B W - - ++ - N - - - 227 194 181 124 98 35 3.5 0 0 5 S 
72 37 M I Fa MP O - - ++ - N - - - 247 221 193 173 162 35 4 0 0 6 S 
73 53 F I Fi C M + + +++ + B - + - 648 727 894 943 1024 120 5 6 8 11 D 
74 30 M A Fa MP W - - ++ - N - - - 193 162 147 132 121 30 3.5 0 0 5 S 
75 32 M I Fa MP M - - ++ - N - - - 211 173 151 123 98 20 3.5 0 0 6 S 
76 39 M I Fa MP O - - ++ - N - - - 252 233 184 167 142 35 4 0 0 5 S 
77 27 F I Fa MP W - - ++ - N - - - 246 212 178 166 145 25 3.5 0 0 5 S 
78 24 M I Fa F W + + +++ + T + + - 844 927 989 1044 1141 110 5 6 8 10 D 
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79 42 M I Fa B W - - ++ - N - - - 247 194 167 171 143 30 3.5 0 0 4 S 
80 45 M I O MP M - - ++ - N - - - 188 176 143 112 99 30 3.5 0 0 4 S 
81 29 F I Fa MO W + + +++ + B + + + 657 728 847 924 1057 110 5.5 8 10 11 D 
82 57 M I I MP W - - ++ - N - - - 256 223 198 178 123 30 4 0 0 5 S 
83 50 M I Fi B W - - ++ - N - - - 184 148 151 112 98 25 3.5 0 0 4 S 
84 24 M I Fa MP O - - ++ - N - - - 212 197 157 143 106 25 3.5 0 0 5 S 
85 31 M I Fa Q W - - ++ - N - - - 358 311 224 197 162 50 4.5 0 3 7 S 
86 54 M I Fi MP W - - ++ - N - - - 258 223 187 138 147 30 4 0 0 6 S 
87 22 F I Fa B M - - ++ - N - - - 194 181 152 124 98 25 3.5 0 0 5 S 
88 28 F I Fa MO M + + +++ + B + + - 844 928 997 1087 1244 130 5.5 6 9 11 D 
89 35 M I Fa MP W - - ++ - N - - - 262 232 178 146 113 30 3.5 0 0 5 S 
90 24 M I Fa C W + + +++ + B - + - 648 729 834 921 1027 110 5 6 8 11 D 
91 43 M I Fa MP O - - ++ - N - - - 312 296 212 179 140 30 4 0 0 6 S 
92 38 F I Fa B W - - ++ - N - - - 211 167 148 151 119 25 4 0 0 6 S 
93 52 M I I MO O - - +++ - B - + - 412 698 874 948 1024 120 5 6 8 11 D 
94 34 F I Fa MP O - - ++ - N - - - 197 168 154 132 119 25 3.5 0 0 5 S 
95 25 M A Fa D W + + ++ - T - - - 227 184 162 141 148 30 4 0 0 5 S 
96 41 M I O MP W - - ++ - N - - - 348 312 298 204 157 35 4.5 0 0 8 S 
97 29 M I Fa Q M - - ++ - N - - - 254 213 174 158 144 40 4 0 0 6 S 
98 53 F I Fi C M + + +++ + B - + - 648 727 894 943 1024 120 5 6 8 11 D 
99 23 M I Fa MP M - - ++ - N - - - 176 152 141 119 97 25 3.5 0 0 4 S 
100 44 M I Fa F O + + +++ + B - + - 778 847 984 1078 1144 120 5 6 7 10 D 
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